Ideas to clinical and commercial assets
Biosyngen Focus on Technological Transfer of Immune Cell Therapy
Headquartered in Singapore, BioSyngen Group is dedicated in the clinical and commercial transfer of innovative immune-cell therapy technologies and products in Asia and China. The Group has closely research collaborations with world-renowned research institutions, jointly develop innovative technologies and products, receives world exclusive licenses of technologies and products. BioSyngen has a comprehensive and resourceful technical platform to support the development of cell therapy products, such as pre-clinical research, supplies of clinical grade virus vectors and mRNA, gamma-delta allogeneic cells, development of companion diagnostics, as well as T cell GMP production and clinical trial management. Founders of Biosyngen Group has jointly founded biotech companies such as Lion TCR, SCG Cell Therapy, BioCheetah.
On its Board of Scientific Advisors are internationally renowned scientists and collaborators, such as 2011 Nobel Laureate Professor Jules Alphonse Hoffman, Research Director CNRS Emeritus at CNRS Professor Jean-Paul Thiery, and Fellow of the Royal Society Professor Sir David Lane. Founded in 2016, through synergistically integrating its resources and network, BioSyngen has efficiently transformed cell therapy and diagnostic projects into clinical development stage. The Group strives to become the leader in biotechnology transfer of innovative immune cell therapy in Asia and China. Currently, BioSyngen conducts clinical trial projects in Singapore, Australia and China.
Virus infection accounts for 1 out of 5 cancer cases in Asia, in particular China. Of the 4.28 million new cancer cases in China in 2018, more than 0.9 million are related to viral infections. The cell surface proteins Human Leukocyte Antigen (HLA) molecules are responsible for the regulation of immune system in humans.
γδ T Cell Therapy
γδ T Cells are Ideal Tools for Cell Therapy
· Inherent recognition and elimination of tumor cells
· Antigen presentation, cytokines/chemokines secretion to activate wide range immune responses
· Harmless to healthy cells
· Improved tissue-penetrating ability......
Gene transduction technology
Target genes such as CAR and TCR are introduced into T cells through gene transduction technology, which enables T cells to deploy target recognition, self-activation and cell killing ability. Biosyngen has established two mature gene transduction technology platforms; including mRNA and lentivirus vectors, and these products have been used in clinical research.
Combination Immune Therapy, Technology and Product
In recent years, CAR-T cell therapy has achieved clinical breakthroughs in the treatment of hematologic cancer, however it is difficult to treat solid tumors.One of the reasons is tumor microenvironmental immunosuppression. Preliminary results have been reported in clinical trials of immunocheckpoint inhibitors and immunomodulators combined in the treatment of solid tumors.
Targeted Therapy and Targeted Diagnosis
Currently, tumor immunotherapy is one of the most promising form of cancer treatments. However, clinical treatment results show independent differences, especially in both CAR-T and TCR-T cell therapy for solid tumors. In some cases, only some patients have sustained remission after cell therapy treatment, and other patients have recurrence after remission.
Prof. Jules Alphonso Hoffman (Nobel Laureate in Physiology or Medicine 2011)，for his research and discovery on the discoveries concerning the activation of innate immunity and TLRs, Prof. Hoffman received Nobel prize in Physiology or Medicine (2011), his work has monumentally advance the research of immunology. He is the Chair of Integrative Biology, Professor of University of Strasbourg Institute for Advanced Study, France. He was former President of French National Academy of Sciences.
Sir./Prof. David Lane, PhD
Prof. Lane is Knight and Fellow of the Royal Society, Chief Scientist at A*STAR Singapore and Director of p53 lab, A*STAR. He is the recipient of numerous academic awards, such as Paul Ehrlich Prize, Josef Steiner Prize, Singapore President’s Science and Technology Medal. He co-founded FogPharma and Cyclacel (Nasdaq listed) and also serves as Chairman of Chugai Pharmabody Research.
Prof. Jean-Paul Thiery, PhD
Prof. Thiery is Knight of the French National Order of Merit (1997), Laureate of French Academy of Medicine (2000), Knight in the French Legion of Honor (2009), Advisor to the Dean of NUS Medical school, Visiting Professor of NUS Medical school, Hong Kong University, Guangzhou Institute of Biomedicine and Health CAS. He published over 480 peer review scientific papers. He is the co-founder of BioCheetah.
Prof. Dr. Wolfgang Hammerschmidt
Director of Department, Research Unit Gene Vectors, Helmholtz Center Munich, and Affiliated Professor at the Ludwig Maximilians-University Munich
Loffler-Frosch Award of the German Society of Virology, Aronson Award of the City of Berlin
Published papers on EBV (Epstein-Barr virus) research
Prof. Dr. Reinhard Zeidler
Professor at the Klinikum der Universität München (KUM) and Group Leader at the Helmholtz Centre Munich
Development of proprietary therapeutic monoclonal antibodies, and Epstein-Barr-Virus and extracellular vesicles
Frank Wang, MBA, Chairman
Mr. Frank Wang has 20 years of experience in strategic planning and international project operation. He has in depth knowledge of China’s economy, culture, and government decision-making process.
Victor Li Lietao, MD, Founder & CEO
Dr. Victor Li has 25 years of biopharma industry experiences and 4 years in clinical practice. He founded his first biotech company and successfully transferred the company upon successful clinical development. He is inventor / co-inventor of over 60 patents. He served as the principal consultant of health industry with PricewaterhouseCoopers(PWC) and as market strategy work with Ciba-Geigy Pharma.
Feiyu Shen, Director of Board
Renowned entrepreneur & investor in China, Chairman of Meilinge Group.
Wang Liqun, Director
Mr. Wang is a rare veteran who transformed from entrepreneur to leading investor and has 30 years of experience leading large enterprises in the Private Equity(PE) industry. He previously held leadership positions as General Manager of Shanghai Public Transportation Group Co., Ltd.; General manager of Shanghai Urban Investment Co., Ltd.; Chairman of Public Transportation Card Co., Ltd.; and Chairman of Rail Transport Co., Ltd.. He also took the lead in introducing international professional events in China and successfully held the Heineken Open and Masters Cup in Shanghai. He founded Stone Capital, which is nominated as "the best 30 domestic investment institutions" by Forbes and Zero2IPO Group for many years.
Fengmao Hua, MBA, Chairman of Board
Mr. Hua has about 20 years of experience in the investment banking business. Mr. Hua previously worked at a number of investment banking firms where he was mainly responsible for corporate finance, public offering, reorganization, merger and acquisitions as well as other financial consulting work of over 200 companies. Mr. Hua was a founding member of VivaBio, where he served as Co-founder, Executive Director and Chief Finance officer. He obtained his MBA from the International University of Japan.
Zhang Qiong, Director of Board
Ms. Zhang is the co-founder of ABC Capital and co-president of ABC Capital group. MSX management from Stanford University Business school, co-founder of 7 days hotel chain (now renamed Platinum Group and acquired by Jinjiang Group). With rich experience in the field of innovative consumption and consumption upgrading, she has led the equity investment of many high-growth and high-quality enterprises, including Avic Sanxin, Fujian Sunner, Shengda Wood and Lijia Baby. As one of the founders and President of ABC Consulting, planned and presided over dozens of enterprise restructuring, restructuring and merger, cross-border merger and post-merger integration, such as Cosco's acquisition of Shanghai Zhongcheng, Shanghai Fangdi Group's acquisition of Jiafeng, Uni-president’s participation in Wondersun dairy; corporate strategic planning and overseas financing and other large projects.
Michelle Chen, Director of Board, Director of HR and Admin
Mrs. Chen has 14 years’ human resource management experience with Fortune Global 500 companies. She is skilled in data mining and analysis, in developing corporate organization strategies and management processes, developing corporate departments, improving personnel performance, and communication skills.
Examples of Biotech Transformation
In July 2015, Dr. Victor Li and Prof. Antonio Bertoletti co-founded Lion TCR Pte. Ltd. in Singapore, the company received the global exclusive in-license from The Agency for Science, Technology and Research(A*STAR) of Singapore, focusing on the development of TCR-T cell therapy for liver cancer, preliminary results in clinical trials have shown the effectiveness of therapy.
Dr. Victor Li of Biosyngen Group founded SCG Cell Therapy Pte. Ltd. together with Prof. Ulrike Protzer from Institute of Virology, The Technical University of Munich (TUM). In July 2018, the company successively obtained the exclusive in-license of Class I and Class II T Cell receptor (TCR) patents related to TCR-T Cell Therapy.
● Opportunity to work with world renowned institutes, with leading scientists that develop innovative technologies and products to solve unmet clinical needs
● Development of innovative Immune cell therapy with emphasis on quality and efficiency and clinical validation of innovative technologies
● Partnering and sharing success with Employees
"We value every employee."
——Dr. Victor Li, Founder of Biosyngen Group